- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01550250
Night-time Compression Systems for Breast Cancer Related Lymphedema
June 29, 2020 updated by: University of Alberta
Feasibility of Night-time Compression Systems for Breast Cancer Related Lymphedema: a Pilot Study
Women who have undergone breast cancer surgery may develop swelling of the arm on the side the breast cancer occurred.
If the swelling becomes chronic it is called lymphedema.
This study will examine night-time compression system garments for lymphedema.
Our objective is to determine if breast cancer survivors are willing and able to use the garment overnight to help control their lymphedema.
Thirty breast cancer survivors from Alberta will be enrolled in the 24-week long study.
Measurements will be taken of each arm to assess the extent of lymphedema and to measure changes over the study period.
We will also examine other outcomes such as the impact of the night-time compression system garment on sleep.
The study will provide important information on the feasibility of night-time compression system garments as a self-management strategy for lymphedema.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2S 3C1
- Holy Cross Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with a histological diagnosis of breast cancer experiencing edema in the ipsilateral arm such that there is a minimum 10% and maximum 40% increase in arm volume over the unaffected arm (mild to moderate lymphedema).
- Patients must have completed all primary and adjuvant treatments (surgery, chemotherapy, radiotherapy) prior to randomization.
- Patients must have their own fitted compression garment for daytime maintenance.
- No past or current use of a night-time compression system for maintenance. Those patients who have trialed a night-time compression system in the past year must observe a six-month washout period before entering the trial.
Exclusion Criteria:
- Clinical or radiological evidence of active disease, either local or metastatic.
- History of contralateral breast cancer and axillary surgery.
- Serious non-malignant disease, such as renal or cardiac failure, which would preclude daily treatment and follow-up.
- Patients for whom compression is contraindicated.
- Psychiatric or addictive disorders which preclude obtaining informed consent or adherence to the protocol.
- Unable to comply with the protocol, measurement and follow-up schedule.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Immediate Night-time Compression
Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system.
Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period.
A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks.
From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
|
Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
Standard care for lymphedema maintenance.
Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
|
|
Active Comparator: Delayed Group: Standard Care
Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance.
Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
|
Standard care for lymphedema maintenance.
Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accrual rate
Time Frame: 18 months
|
The number of women eligible for the study and number agreeing to participate.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence
Time Frame: 24 weeks
|
Data on adherence to wearing the night-time compression system.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Margaret L. McNeely, PhD, University of Alberta and Alberta Health Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
March 7, 2012
First Submitted That Met QC Criteria
March 7, 2012
First Posted (Estimate)
March 9, 2012
Study Record Updates
Last Update Posted (Actual)
July 1, 2020
Last Update Submitted That Met QC Criteria
June 29, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACREC-25845
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Emory UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary CarcinomaUnited States
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingBreast Cancer | Triple -Negative Breast CancerChina
Clinical Trials on Night-time compression system garment
-
AHS Cancer Control AlbertaCross Cancer InstituteCompletedBreast Cancer | LymphedemaCanada
-
University Hospital Schleswig-HolsteinCompleted
-
ThuasneInternational Clinical Trials AssociationCompletedLymphedema of Upper ArmFrance, Turkey
-
University of Colorado, DenverNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Recruiting
-
Isabel Forner-Cordero, MD, PhDHospital Arnau de Vilanova; Hospital Provincial de CastellonRecruiting
-
University of Colorado, DenverColorado Joint Replacement; mediCompleted
-
Hôpital Raymond PoincaréUnknownHypermobility Type Ehlers-Danlos SyndromeFrance
-
University of OklahomaTerminated
-
University of CalgaryCompleted
-
Nationwide Children's HospitalCompletedSyncope | Postural Orthostatic Tachycardia Syndrome (POTS)United States